Kerstin Wollschlaeger
Universitaets Frauenklinik, Gerhart Hauptmann Str. 35
Magdeburg, ST 39108, Germany
Magdeburg, ST 39108, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
Journal: British journal of cancer
Published: October 11, 2021
Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914].
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 30, 2016
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Journal: British journal of clinical pharmacology
Published: January 20, 2015
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study.
Journal: British journal of cancer
Published: September 01, 2014
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 13, 2014
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Journal: Breast cancer research and treatment
Published: May 15, 2013
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 24, 2012
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Journal: Gynecologic oncology
Published: March 09, 2012
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 02, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026